ACTION: Meeting notice.

SUMMARY: Notice of this meeting is being provided according to the requirements of the Federal Advisory Committee Act, 5 U.S.C. App. 10(a)(2). This notice provides the schedule and agenda for the January 25, 2016 meeting of the World War One Centennial Commission (the Commission). The meeting is open to the public.

DATES: The meeting will be held on Monday, January 25, 2016 starting at 10 a.m. Eastern Standard Time (EST), and ending no later than 12:30 p.m., (EST).

ADDRESSES: The meeting will be held at the office of the Jones Day Law firm at 51 Louisiana Ave. NW., Washington, DC 20001–2105. This location is handicapped accessible. The meeting will be open to the public and will also be available telephonically. Persons attending in person are requested to refrain from using perfume, cologne, and other fragrances (see *http://www.accessboard.gov/about/policies/fragrance.htm for more information*).

Persons wishing to listen to the proceedings may dial 712–432–1001 and enter access code 474845614. Note this is not a toll-free number. Written Comments may be submitted to the Commission and will be made part of the permanent record of the Commission. Comments must be received by 5:00 p.m., (EST), January 21, 2016, and may be provided by email to: *daniel.dayton@worldwar1centennial.org.* Contact Daniel S. Dayton at *daniel.dayton@worldwar1centennial.org* to register to comment in person during the meeting's 30 minute public comment period.

Registered speakers/organizations will be allowed 5 minutes and will need to provide written copies of their presentations. Requests to comment at the meeting must be received by 5 p.m. Eastern time, January 21, 2016. Written presentations may be provided to Mr. Dayton at *daniel.dayton@worldwar1centennial.org* until Thursday, January 21, 2016. Please contact Mr. Dayton at the email address above to obtain meeting materials.

FOR FURTHER INFORMATION CONTACT: Daniel S. Dayton, Designated Federal Officer, World War 1 Centennial Commission, 701 Pennsylvania Avenue NW., 123, Washington, DC 20004–2608, at 202–380–0725 (note: this is not a toll-free number).

SUPPLEMENTARY INFORMATION:

Background

The World War One Centennial Commission was established by Public Law 112–272 (as amended (Pub. L. 113–291, div. B, S3091, Dec. 19, 2014)), as a commission to ensure a suitable observance of the centennial of World War I, to provide for the designation of memorials to the service of members of the United States Armed Forces in World War I, and for other purposes.

Under this authority, the Committee will plan, develop, and execute programs, projects, and activities to commemorate the centennial of World War I, encourage private organizations and State and local governments to organize and participate in activities commemorating the centennial of World War I, facilitate and coordinate activities throughout the United States relating to the centennial of World War I, serve as a clearinghouse for the collection and dissemination of information about events and plans for the centennial of World War I, and develop recommendations for Congress and the President for commemorating the centennial of World War I. The Commission does not have an appropriation and operated solely on donated funds.

Agenda: Monday, January 25, 2016

Old Business

- Approval of minutes of previous meetings
- Public Comment Period

New Business

- Commission Operating Status
- Requests for Support
- WWI Memorial at Pershing Park—Discussion and Vote
- International Report
- Chairman's Report
- Next Meeting

Other business as may properly come before the Commission Adjourns.

Dated: January 13, 2016.

Daniel S. Dayton,

Designated Federal Official, World War I Centennial Commission.

[FR Doc. 2016–00911 Filed 1–15–16; 8:45 am]

BILLING CODE 6820–95–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number CDC–2015–0075; NIOSH–288]

Request for Information on Development of a Performance Test Protocol for Closed System Transfer Devices That Incorporate Air-Cleaning Technology To Provide Worker Protection During Pharmacy Compounding and Administration of Hazardous Drugs

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Request for information and comment.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) requests information for the development of a test protocol to evaluate the performance of closed system drug-transfer devices (CSTDs) that adopt air-cleaning technologies. CSTDs are generally available in two design types: (1) One that uses a physical barrier to block the unintended release of drug into the surrounding environment or the intake of environmental contaminants into the sterile drug pathway and (2) one that uses air cleaning or filtration technologies to prevent the unintended release of drug into the surrounding environment or the intake of environmental contaminants into the sterile drug pathway. A draft protocol titled, ''A Vapor Containment Performance Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs,'' was developed by NIOSH to evaluate how protective the physical barrier-type CSTD devices were as an indicator of how effective they would be at preventing hazardous drug escape from the closed system.

This RFI seeks information from the public regarding the feasibility of developing a protocol applicable to CSTDs using air cleaning or filtration technologies and to request information from stakeholders on this topic.

Table of Contents

- BACKGROUND:
- INFORMATION NEEDS:

DATES: Electronic or written comments should be received on or before March 8, 2016.

ADDRESSES: You may submit comments identified by CDC–2015–0075 and Docket Number NIOSH–288 by any of the following methods:

- *Federal eRulemaking Portal: http://www.regulations.gov.* Follow the instructions for submitting comments.
- *Mail:* National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, OH 45226–1998.

Instructions: All information received in response to this notice must include the agency name and docket number (CDC–2015–0075; NIOSH–288). All relevant comments received will be posted without change to *www.regulations.gov,* including any personal information provided. For access to the docket to read background documents or comments received, go to *www.regulations.gov.* All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226.

FOR FURTHER INFORMATION CONTACT: Gayle DeBord, NIOSH, Division of Applied Research and Technologies, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–R2, Cincinnati, Ohio 45226, Phone: (513) 841–4256 [not a toll-free number], Email: *hazardousdrugs@cdc.gov.*

Background: The purpose of the RFI is to seek information relative to the development of a performance evaluation protocol for CSTDs using air cleaning or filtration technologies. The draft protocol released for public comment on September 8, 2015 [80 FR 53802] is applicable to barrier-type CSTDs only. This RFI expands the scope of the previous RFI to seek information to support development of a companion protocol that would apply to CSTDs using air cleaning or filtration technologies, thus covering the remainder of the currently known CSTD marketplace.

Information Needs: Additional data and information are needed to assist NIOSH to develop or adapt a test protocol for evaluating the efficiency of air cleaning or filtration technologies CSTDs. In particular, NIOSH requests submission of existing test protocols developed for efficacy testing of air cleaning or filtration technologies CSTDs.

The National Institute for Occupational Safety and Health seeks public comments in response to the following questions. Please feel free to comment on any or all of the questions below:

1. Are there any other types of CSTDs available that would not fit into the two categories described, *i.e.,* (1) barrier systems, and (2) air-cleaning or filtration technologies?

2. Is there an existing test protocol for evaluation of the protective efficacy of air-cleaning or filtration technologies CSTDs? Can this test protocol, and/or the details of the underlying procedures and test data be shared with NIOSH?

Please apply the following questions to a protocol you have developed, one you are aware of, or one you believe to be feasible to develop:

3. Are there any special restrictions, limiting assumptions or requirements for expertise required to conduct the protocol?

4. What are the performance criteria used with the protocol tests to determine acceptability and judge conformity?

4. Does the protocol apply to compounding operations, administration activities or both?

5. Does this protocol use a surrogate or does it require testing against the actual hazardous drugs?

6. If a surrogate is used,

a. Does the surrogate represent all hazardous drugs or a subset?

b. Which criteria are used in selection of the surrogate?

c. Describe how the selection criteria address the degree to which the surrogate or surrogates are representative of the class of hazardous drugs to which they apply.

d. Does the surrogate introduce any potential worker exposure hazards?

7. List the hazardous drugs for which this protocol has been used.

a. How were these hazardous drugs selected?

b. Were there any hazardous drugs for which the test protocol was not or would not be successful or compatible?

c. During protocol application, in what state were the hazardous drugs, *e.g.,* full strength as delivered, full strength reconstituted, patient dose with diluent, or drug cocktail?

8. What procedure(s) can be used to verify that the protocol is applicable for new hazardous drugs as they are identified and brought to market?

9. Can the test protocol be used effectively for different formulations of the same active pharmaceutical ingredient?

10. If applicable, are you willing to share details of your test protocol with NIOSH? Would you be willing for the protocol details to be shared publicly or would you require the test protocol details to be protected as proprietary information?

11. If applicable, are you willing to share test results from the application of your air cleaning or filtration technologies CSTD test protocol with NIOSH?

12. Are you interested in being a collaborative partner with NIOSH on the development of an air cleaning or filtration technologies CSTD test protocol?

Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract or to issue a grant. Information obtained as a result of this RFI may be used by the government for program planning on a non-attribution basis. Please do not include any information that might be considered proprietary, confidential, or personally identifying (such as home address or social security number).

Dated: January 12, 2016.

John Howard,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2016–00827 Filed 1–15–16; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–16–15BBU]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and